# Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

> **NCT00083161** · PHASE2 · COMPLETED · sponsor: **Gundersen Lutheran Health System** · enrollment: 8 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** cisplatin
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide

## Key facts

- **NCT ID:** NCT00083161
- **Lead sponsor:** Gundersen Lutheran Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2012-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083161, "Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00083161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*